Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.
In a recent study published in the Journal of Psychopharmacology, researchers conducted a web-based international survey with 541 participants who self-reported a diagnosis of bipolar disorder (BP) and had used psilocybin to achieve a “full psychedelic trip” (1). In addition to multiple choice questions, the survey also offered the option for respondents to answer an open-ended question and leave comments about their experiences with psilocybin.
“Before we run clinical trials to investigate the effectiveness of psilocybin for people with bipolar disorder, we need to know whether it’s safe for them to use, as some medications which have a similar neurobiological mechanism of action can trigger manic episodes,” said study author Emma Morton, a Canadian Institutes of Health Research Banting Postdoctoral Fellow at the University of British Columbia (2). “That’s why we turned to community members to ask about their experiences.”
Responses to survey questions indicated mixed experiences to psilocybin (2). On average, participants rated the harmfulness of their experience as 1.6 out of 5, and the helpfulness as a 4. However, a third of respondents reported new or increasing manic symptoms, difficulty sleeping, and anxiety. Use of emergency medical services occurred for 18 participants and was considered rare in this study.
“Respondents (even those who experienced adverse effects) indicated that psilocybin use was more helpful than harmful,” read part of the results (2). “Quantitative findings elaborated on perceived benefits, as well as the potential for psilocybin trips to contain both positively and negatively received elements.”
Following the Phase I study, interviews with 15 of the respondents were conducted to further understand their psilocybin use to determine the cause of negative outcomes. “We learned that contextual factors like dose, setting, use of other substances, or pre-existing sleep problems, may have had a role in whether people experienced positive or negative outcomes,” Morton explained. “This finding emphasizes how important it will be to conduct additional research under controlled conditions to be more confident about the potential risks and benefits of psilocybin use for bipolar disorder.”
“Our findings demonstrate both benefits and risks of psilocybin use in this population,” read part of the conclusion (3). “Carefully designed clinical trials focused on safety and preliminary efficacy are warranted.”
References
California Moves to Cement Emergency Rules Restricting Hemp-Derived Products
June 18th 2025Proposed regulations from the Department of Health would make permanent the emergency rules banning THC in hemp-derived food, beverage, and dietary products while restricting sales to adults 21 and older.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.
Global Survey Examines Cannabis Use over Pharmaceuticals for Endometriosis Symptom Relief
June 17th 2025A survey of nearly 900 endometriosis patients across 28 countries highlights cannabis as a preferred alternative to pharmaceuticals, despite legal, social, and medical communication barriers.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.